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E-mail address: b.gilmore@qub.ac.uk (B.F. GilmoreThe metalloproteases ZapA of Proteus mirabilis and LasB of Pseudomonas aeruginosa are known to be vir-
ulence factors their respective opportunistic bacterial pathogens, and are members of the structurally
related serralysin and thermolysin families of bacterial metalloproteases respectively. Secreted at the site
of infection, these proteases play a key role in the infection process, contributing to tissue destruction and
processing of components of the host immune system. Inhibition of these virulence factors may therefore
represent an antimicrobial strategy, attenuating the virulence of the infecting pathogen. Previously we
have screened a library of N-alpha mercaptoamide dipeptide inhibitors against both ZapA and LasB, with
the aim of mapping the S10 binding site of the enzymes, revealing both striking similarities and important
differences in their binding preferences. Here we report the design, synthesis, and screening of several
inhibitor analogues, based on two parent inhibitors from the original library. The results have allowed
for further characterization of the ZapA and LasB active site binding pockets, and have highlighted the
possibility for development of broad-spectrum bacterial protease inhibitors, effective against enzymes
of the thermolysin and serralysin metalloprotease families.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Extracellular secreted metalloproteases are widely distributed
amongst bacteria, and have been identiﬁed in both Gram-positive
and Gram-negative species. The proposed function of such proteo-
lytic enzymes in bacterial physiology has been postulated as the
digestion of complex protein substrates in the surrounding envi-
ronment, to provide simple nutrients for the bacterial cell [1].
However, many extracellular metalloproteases from pathogenic
organisms that have been investigated to date have revealed them
as important contributors to virulence [2].
Two major families of bacterial metalloproteases have been
identiﬁed, the thermolysin (M4) and serralysin (M10) families. Of
all the bacterial metalloproteases the most thoroughly character-
ized is thermolysin, a heat stable metalloprotease produced by
Bacillus thermoproteolyticus [2]. Although structurally related to
the thermolysin family, serralysins differ in that they exploit three
histidine residues and a tyrosine to coordinate the zinc ion in the
active site, whereas thermolysin-like metalloproteases use two
histidine and a glutamic acid residue [3]. Other differences in the
active site also exist, for example in serralysins the zinc bindingll rights reserved.
).motif extends to HEXXHXXGXXH, whereas thermolysins have a
consensus sequence NEXXSD [4,5]. Serralysin metalloproteases
are generally inhibited by conventional metal-chelating agents,
such as EDTA and thiols, but they are insensitive to phosphorami-
don and Zincov, which are speciﬁc inhibitors of the thermolysins
[6].
Two speciﬁc examples of bacterial metalloprotease virulence
factors are LasB (also known as Pseudolysin or Pseudomonas elas-
tase) produced by Pseudomonas aeruginosa, and ZapA (also known
as Mirabilysin) produced by Proteus mirabilis. These metallopro-
teases are members of the thermolysin and serralysin families
respectively. It has been demonstrated that each of these bacterial
proteases functions as a virulence factor during the process of
infection, each having a deleterious effect on the host including
the degradation of a broad range of host tissue proteins, and bio-
molecules involved in innate immunity such as immunoglobulins,
complement factors, antimicrobial peptides and cytokines [7–12].
In addition, LasB acts within the bacterial cell as a regulator of
polysaccharide (alginate) secretion [13]. This extracellular polysac-
charide (EPS) is a key constituent of the pseudomonal bioﬁlm [14],
a protected mode of growth where antimicrobial tolerance can be
up to 1000-fold that of a planktonic population [15].
P. aeruginosa is recognized as a key pathogen in chronic infec-
tion of the cystic ﬁbrosis (CF) lung with such infections displaying
ME-(X)-Tyr ME-Trp-(X)
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tion, impeding the normal clearance of bacteria. LasB is a potential
underlying trigger of this sustained inﬂammatory environment
due to its ability to cause direct damage of host tissue and process-
ing of immune system components, and also its important role in
bioﬁlm formation, leading to an infection highly resistant to antibi-
otic therapy [13,16–20].
We have recently have characterized the importance of ZapA as
a virulence factor in a rat model of P. mirabilis induced acute and
chronic prostatitis, and have found this virulence factor essential
in progression to chronic infection [21]. The underlying mecha-
nism of virulence attributed to the production of ZapA was not
found to be bioﬁlm mediated, unlike role of LasB in P. aeruginosa
bioﬁlms [13,21].
Due to the contribution of these two importantmetalloproteases
to the virulence of their respective bacterial pathogens, inhibition of
ZapA and LasB could represent novel anti-virulence targets for ther-
apeutic intervention. The inhibition of bacterial virulence factors
would present an antimicrobial strategy that is non-destructive,
attenuating virulence mechanisms without directly challenging
bacterial cell viability. Such an approach would potentially prevent
the emergence of resistant strains, as little or no selective pressure is
placed on the bacterial cell.
We have previously reported, the synthesis and kinetic charac-
terization of a library of N-alpha mercaptoamide dipeptides as
inhibitors of both ZapA and LasB, and this has revealed important
information regarding the binding preferences of these enzymes,
and has highlighted both striking similarities and important differ-
ences between the two. Both metalloproteases exhibited a prefer-
ence for large aromatic residues in the P10 position of the dipeptide
inhibitor, and aliphatic residues in P20. However, for ZapA, the abil-
ity of the aromatic residue in P10 to hydrogen bond appeared
important in inhibitor binding, whereas this was not important
for the inhibition of LasB [22–24].
It is proposed that derivitizing these inhibitors with functional-
ities lending a high degree of non-polar character, such as halo-
gens, binding to the active site of LasB and ZapA might be
improved. In addition, derivatization with halogens may also im-
prove inhibitor binding to ZapA through the process of halogen
bonding, an interaction that is analogous to hydrogen bonding
[25,26]. This study investigates several analogues of inhibitors
from the original N-alpha mercaptoamide dipeptide library. These
analogues contained halogenated or otherwise substituted phenyl-
alanine to assess the effect of substitution of the aromatic ring on
inhibitor performance. Cyclohexyl-L-alanine (CHA) was also used
to assess the effects of the loss aromaticity from the inhibitor
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Fig. 1. Structures of synthesized N-alpha mercaptoamide inhibitor analogues.2. Materials and methods
2.1. Materials
3,4-Dimethoxy phenylalanine (DMOPA) was obtained from
Sigma–Aldrich (Dorset, UK). All remaining amino acids, amino acid
analogues, S-trityl-mercaptoacetic acid, and the coupling reagents
O-benzotriazole-N,N,N0,N0-tetramethyl-uronium-hexaﬂuorophos-
phate (HBTU) and 1-hydroxybenzotriazole (HOBt), were obtained
from Peptides International (Louisville, USA). Rink amide resin
(200–400 mesh) was obtained from Bachem (UK) Ltd. (Meyerside,
UK). Dimethylformamide (DMF), dichloromethane (DCM), piperi-
dine, and diisopropylethylamine (DIPEA) were obtained from
Sigma–Aldrich (Dorset, UK).
LasB (Pseudolysin) was obtained from Elastin Products Com-
pany (MO) and stored at 80 C in aliquots of 100 lg/ml stock
solution in assay buffer containing 0.05 M Tris–HCl, 2.5 mM CaCl2,pH 7.2, until required. ZapA was puriﬁed directly from culture
supernatants of P. mirabilis BB2000, as described previously [23],
and stored in at 80 C in aliquots of 100 lg/ml stock solution in
assay buffer containing 0.05 M Tris–HCl, 2.5 mM CaCl2, pH 8.0.
The ﬂuorogenic substrate, Aminobenzoyl-Ala-Gly-Leu-Ala-p-
Nitro-Benzyl-Amide, was supplied by Peptides International
(Louisville, USA).
2.2. Synthesis of inhibitors
Inhibitors were synthesized using a methodology previously
described [22,27], using a CEM Liberty microwave assisted peptide
synthesizer and standard Fmoc solid-phase peptide synthesis pro-
tocols on Rink amide resin. Amino acid analogues were incorpo-
rated under standard coupling conditions. The identity and purity
of all the synthesized inhibitors were conﬁrmed by electrospray
mass spectrometry and reverse phase (C18) HPLC analysis. Struc-
tures of synthesized inhibitor derivatives are illustrated in Fig. 1.
2.3. Kinetic screening
Each inhibitor was screened against both LasB and ZapA using a
microtitre-based ﬂuorimetric assay. Hydrolysis of the ﬂuorogenic
substrate Aminobenzoyl-Ala-Gly-Leu-Ala-p-Nitro-Benzyl-Amide
by each metalloprotease was carried out in assay buffer (50 mM
Tris–HCl, 2.5 mM CaCl2, pH 7.2 for LasB; 50 mM Tris–HCl,
2.5 mM CaCl2, pH 8.0 for ZapA). Changes in ﬂuorescence were
monitored by a BMG FLUOstar OPTIMA ﬂuorescence microtitre
plate reader at an excitation wavelength of 330 ± 10 nm and an
emission wavelength of 460 ± 10 nm. Each inhibitor was investi-
gated over a concentration range between 1 lM and 50 lM in
order to determine accurate kinetic parameters (Ki). Previous
observations have revealed that these inhibitors do not ﬁt the stan-
dard linear transformation required for determination of Ki
via Michaelis–Menton kinetics [22,23], therefore Ki values were
Table 1
Ki values (lM) for the N-alpha mercaptoamide parent inhibitors and inhibitor
analogues against ZapA of Proteus mirabilis and LasB of Pseudomonas aeruginosa.
Parent inhibitor ZapA LasB Inhibitor analogue ZapA LasB
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on GraphPad Prism software (version 5). An example of a typical
progress curve for the inhibition of protease-mediated substrate
hydrolysis is shown in Fig. 2.Ki (lM) Ki (lM)
ME-Phe-Tyr 10.50 0.04 ME-Phe(Cl)-Tyr 6.15 0.31
ME-Phe(Br)-Tyr 7.73 0.03
ME-DMOPA-Tyr 13.38 1.04
ME-Phe(F)-Tyr 17.67 0.04
ME-CHA-Tyr 56.53 0.51
ME-Trp-Phe 38.52 11.00 ME-Trp-CHA 5.87 0.16
ME-Trp-DMOPA 7.86 4.30
ME-Trp-Phe(Cl) 8.52 0.02
ME-Trp-Phe(Br) 8.91 0.03
ME-Trp-Phe(F) 17.84 0.053. Results
3.1. Inhibitor analogue screening against ZapA
During the screening of the N-alpha mercaptoamide dipeptide
inhibitors against LasB by Cathcart et al. [22,24], it was noted that
lead compounds possessed non-polar side chains that were often
bulky and aromatic. It was proposed that derivatization of these
compounds with functionalities lending a high degree of non-polar
character, such as halogens, binding to the active site of LasB might
be improved. Fluorinated functionalities are becoming more com-
mon in drug candidates, due to the strong electron-withdrawing
effects of the halogen atom, which can produce favourable effects
on interaction with target proteins. Examples of organoﬂuorine
compounds currently in clinical use include Lipitor (atorvastatin),
Prozac (ﬂuoxetine) and Ciprobay (ciproﬂoxacin) [28]. Consider-
ing the similarities between lead compounds identiﬁed for ZapA
and LasB, as discussed previously, these inhibitor analogues were
also screened against ZapA. These analogues included those with
substituted phenylalanine residues, or the non-aromatic cyclo-
hexyl-L-alanine.
The results presented in Table 1 demonstrate that for the inhi-
bition of ZapA, substitution of phenylalanine with chlorine or bro-
mine has a beneﬁcial inﬂuence on Ki in the P10 position, when
compared to the parent compound, SH–CH2–CO–Phe-Tyr–NH2.
DMOPA or p-ﬂuoro phenylalanine showed no improvement, while
loss of aromaticity with CHA in P10 has a largely detrimental effect
on Ki, indicating that aromatic side chains are of particular impor-
tance at the S10 binding pocket of ZapA. The improvement in Ki as
shown by SH–CH2–CO–Phe(Cl)–Tyr–NH2 and SH–CH2–CO–
Phe(Br)–Tyr–NH2 is possibly due to the electron-withdrawing ef-
fect of halogen substituents in the aromatic ring. These atoms are
strongly electronegative, attracting the electron cloud from the
aromatic ring, leaving a partial positive charge, which can in turn
participate in electrostatic interactions through the attraction of
lone electron pairs on another heteroatom. Alternatively interac-
tion with the active site of ZapA may also be a result of the halogen
substituent participating in halogen bonding. Halogen bondingFig. 2. Typical progress curves for hydrolysis of Aminobenzoyl-Ala-Gly-Leu-Ala-p-Nitrob
Phe(Cl)-Tyr–NH2.(XB) is a direct parallel to hydrogen bonding (HB), the difference
being that in HB a hydrogen acts as an electron acceptor, while
in XB the halogen acts as an electron acceptor. Chlorine, bromine
and iodine all participate in halogen bonding, although it is not
thought that ﬂuorine can form halogen bonds, but are more likely
to serve as hydrogen bond acceptors [25,26]. This may explain the
failure of p-ﬂuoro phenylalanine in P10 to improve Ki in the same
manner as p-bromo phenylalanine or p-chloro phenylalanine.
All inhibitor analogues with the derivatized phenylalanine or
CHA in the P20 position improved the Ki over that of the parent
compound, SH–CH2–CO–Trp-Phe–NH2. The mechanism by which
these inhibitor analogues improve inhibitor binding is much more
difﬁcult to assess than those previously discussed with modiﬁca-
tions in the P10 position. This is due to the range of both aliphatic
and aromatic residues found in the P20 position of the inhibitors
that performed well against ZapA, as reported in our previous
investigation [23]. However, it is clear that by modiﬁcation of the
parent compound with these substituted phenylalanine residues
or CHA has improved binding to the S20 pocket of the ZapA active
site, and is possibly a result of non-speciﬁc hydrophobic
interaction.3.2. Inhibitor analogue screening against LasB
Table 1 also reveals that in the case of LasB, halogenated inhib-
itor side chains had a positive effect in inhibitor binding when used
in the P20 position, in agreement with the preference for bulkyenzyl-Amide by ZapA in the presence of a range of concentrations of SH–CH2–CO–
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viously [22]. In this position, the halogenated phenylalanine
surpasses the parent compound SH–CH2–CO–Trp-Phe–NH2
(Ki = 11.00 lM) with Ki values in the nano molar range (SH–CH2–
CO–Trp-Phe(Cl)–NH2 Ki = 0.02 lM, SH–CH2–CO–Trp-Phe(Br)–NH2
Ki = 0.03 lM, and SH–CH2–CO–Trp-Phe(F)–NH2 Ki = 0.05 lM), pos-
sibly a result of the electronegative properties of the halogen
substituent, as discussed above. Halogenated residues in the P10
position pose little beneﬁt in inhibitor binding to LasB, in fact
p-chloro phenylalanine in P10 imposes a detrimental effect on
inhibitory potency, with a Ki of 0.31 lM in comparison to the par-
ent compound SH–CH2–CO–Phe-Tyr–NH2, Ki = 0.04 lM.
The Ki values obtained for the non-aromatic CHA in P10 suggest
that aromaticity is important for optimal inhibitor binding. DMOPA
also has a deleterious effect on binding to the LasB S10 pocket,
likely due to the introduction of a degree of polarity to the P10 po-
sition of the inhibitor, and we have previously documented a pref-
erence for non-polar hydrophobic residues in the LasB S01 binding
pocket [22,24].4. Discussion
In this study we have expanded on our previous knowledge of
the binding preferences of both ZapA and LasB, two distinct bacte-
rial metalloprotease virulence factors from the serralysin and
thermolysin families respectively. Although members of different
metalloprotease families, these two proteases are structurally
related, both belonging to protease clan MA. These fundamental
differences, yet underlying similarities, have been reﬂected in our
previously reported data [22–24], and further supported by this
study by direct comparison of ZapA and LasB using a number of
inhibitor analogues, developed from our original library of N-alpha
mercaptoamide dipeptides.
For both ZapA and LasB, the inhibitor P10 residue has been con-
ﬁrmed as themost important structural feature of the inhibitor dic-
tating binding speciﬁcity [22–24], however inhibitor screening
studies have highlighted a subtle, yet important difference between
these two proteases. While inhibitors containing aromatic residues
in P10 have proved superior for both, ZapA appears to require an aro-
matic residue with the ability to hydrogen bond [23]. This present
study has conﬁrmed our previous observations using halogenated
phenylalanine residues in P10. These halogenated residues convey
the ability to halogen bond (analogous to hydrogen bonding) with
the S10 pocket of the ZapA active site, dramatically improving the
Ki over that of the parent compound containing unsubstitutedphen-
ylalanine.With LasB, the effect of introducing a halogenated residue
at P10 did not produce as dramatic an effect, although replacing the
aromatic amino acid with CHA had a negative effect on binding. The
negative effect of CHA in P10 was also seen with ZapA.
While we have previously concluded that the P20 residue is not
a driving determinant of inhibitor binding in either LasB or ZapA,
this study has demonstrated that with a favourable residue in
P10, binding can be improved through the introduction of a haloge-
nated aromatic residues in P20; a trend observed for both proteases.
The trends highlighted by this study, taken in consideration
with previously published observations [22–24], indicate that it
may be possible to design a single active-site directed inhibitor
that may be effective against metalloprotease virulence factors of
different protease families, and from different species of bacteria.
The implications of such a development would be broad-spectrum,
anti-infective strategy, the mechanism of which is an anti-viru-
lence approach, rather than causing bacterial death or damage,
therefore the development of resistance to such therapeutic strat-
egies is considered less likely to develop than with conventional
antibiotics. Given that many extracellular secreted bacterialmetalloproteases acting as virulence factors during infection share
common evolutionary origins [29], it is anticipated that an ex-
tended range of such virulence factors from a variety of bacterial
pathogens may be targeted using the fundamental principles high-
lighted in this study.
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